- Report
- May 2024
- 138 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- May 2024
- 132 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- March 2025
- 196 Pages
Global
From €4724EUR$4,950USD£3,958GBP
- Clinical Trials
- June 2024
- 180 Pages
Global
From €2386EUR$2,500USD£1,999GBP
- Report
- June 2024
- 200 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Clinical Trials
- November 2024
- 893 Pages
Global
From €3293EUR$3,450USD£2,759GBP
- Report
- August 2022
United States
From €1851EUR$1,940USD£1,551GBP
- Report
- January 2022
- 60 Pages
Global
From €3770EUR$3,950USD£3,159GBP
- Report
- January 2022
- 60 Pages
Global
From €3770EUR$3,950USD£3,159GBP
- Report
- May 2023
- 528 Pages
Global
From €2386EUR$2,500USD£1,999GBP
- Report
- July 2022
- 27 Pages
Global
From €3813EUR$3,995USD£3,195GBP
- Report
- August 2022
Global
From €945EUR$990USD£792GBP
- Clinical Trials
- March 2020
- 421 Pages
Global
From €2386EUR$2,500USD£1,999GBP
- Report
- August 2023
- 85 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- November 2022
- 79 Pages
Global
From €1909EUR$2,000USD£1,599GBP

Macular Edema Drug is a type of drug used to treat macular edema, a condition in which fluid accumulates in the macula, the central part of the retina. This accumulation of fluid can cause vision loss and other vision problems. Macular Edema Drugs are used to reduce the swelling and improve vision. These drugs can be administered orally, intravenously, or intravitreally. Commonly used Macular Edema Drugs include corticosteroids, anti-VEGF agents, and non-steroidal anti-inflammatory drugs.
Macular Edema Drugs are part of the larger Optical Disorders Drugs market, which includes drugs used to treat a variety of eye conditions, such as glaucoma, cataracts, and age-related macular degeneration. These drugs are used to improve vision, reduce pain, and slow the progression of the disease.
Some companies in the Macular Edema Drug market include Allergan, Regeneron, Novartis, and Roche. Show Less Read more